---
title: "AFMDQ.US (AFMDQ.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AFMDQ.US/news.md"
symbol: "AFMDQ.US"
name: "AFMDQ.US"
parent: "https://longbridge.com/en/quote/AFMDQ.US.md"
datetime: "2026-03-07T09:06:37.242Z"
locales:
  - [en](https://longbridge.com/en/quote/AFMDQ.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AFMDQ.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AFMDQ.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/AFMDQ.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/AFMDQ.US/news.md)


# AFMDQ.US (AFMDQ.US) — Related News

### [Affimed Announces Receipt of Nasdaq Delisting Notice](https://longbridge.com/en/news/240142814.md)
*2025-05-14T10:45:00.000Z*
> Affimed N.V. has received a delisting notice from Nasdaq due to public interest concerns following its insolvency filing

### [Affimed NV Delays 2024 Annual Report Filing Due to Liquidity Concerns](https://longbridge.com/en/news/238487084.md)
*2025-05-01T20:07:34.000Z*
> Affimed N.V. has delayed its Annual Report filing for the financial year ended December 31, 2024, due to liquidity conce

### [Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting](https://longbridge.com/en/news/238085485.md)
*2025-04-29T14:00:00.000Z*
> Affimed N.V. presented findings at the AACR Annual Meeting showing that higher exposure to AFM24 in patients with refrac

### [Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement](https://longbridge.com/en/news/236766864.md)
*2025-04-21T10:30:00.000Z*
> Affimed N.V. has received a notice from Nasdaq indicating that its common shares have closed below the minimum bid price

### [Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting](https://longbridge.com/en/news/233176178.md)
*2025-03-25T21:10:26.000Z*
> MANNHEIM, Germany, March 25, 2025 ( GLOBE NEWSWIRE ) -- Affimed N.V. ( Nasdaq: AFMD ) , a clinical-stage immuno-oncology

### [Affimed to Present at the Leerink Partners Global Healthcare Conference 2025](https://longbridge.com/en/news/230321055.md)
*2025-03-03T12:34:43.000Z*
> MANNHEIM, Germany, March 03, 2025 ( GLOBE NEWSWIRE ) -- Affimed N.V. ( Nasdaq: AFMD ) ( "Affimed", or the "Company" ) , 

### [Affimed Reports Positive Data From AFM24-102 Trial In Heavily Pretreated NSCLC Patients](https://longbridge.com/en/news/222554456.md)
*2024-12-17T12:17:10.000Z*
> Affimed N.V. (AFMD) announced positive results from the AFM24-102 trial, which evaluated the AFM24/atezolizumab combinat

### [Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFMD Stock News](https://longbridge.com/en/news/221836581.md)
*2024-12-09T18:30:00.000Z*
> Affimed N.V. reported promising Phase 1 results for AFM28, a bispecific innate cell engager targeting CD123 and CD16A, i

### [Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer](https://longbridge.com/en/news/221802257.md)
*2024-12-09T12:06:29.000Z*
> MANNHEIM, Germany, Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Affimed N.V. ( Nasdaq: AFMD ) ( "Affimed", or the "Company" ) , a

### [Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients | AFMD Stock News](https://longbridge.com/en/news/221734938.md)
*2024-12-08T17:00:00.000Z*
> Affimed N.V. announced positive results from a study on the combination of acimtamig and AlloNK® for treating relapsed/r